Beta Bionics (NASDAQ:BBNX) Trading Down 9.2% on Analyst Downgrade

Beta Bionics, Inc. (NASDAQ:BBNX)’s stock price dropped 9.2% during mid-day trading on Monday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The stock traded as low as $17.83 and last traded at $18.28. Approximately 378,461 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 1,697,192 shares. The stock had previously closed at $20.14.

Several other research firms have also recently issued reports on BBNX. Piper Sandler reiterated an “overweight” rating and issued a $32.00 price objective (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. The Goldman Sachs Group boosted their price objective on Beta Bionics from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Robert W. Baird set a $28.00 target price on Beta Bionics in a research note on Tuesday, December 16th. Lake Street Capital upped their price target on shares of Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday. Finally, Truist Financial lifted their price objective on shares of Beta Bionics from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.20.

Insider Activity

In other Beta Bionics news, Director Adam Lezack sold 1,406 shares of Beta Bionics stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $26.87, for a total transaction of $37,779.22. Following the transaction, the director directly owned 9,841 shares in the company, valued at approximately $264,427.67. The trade was a 12.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Maria Palasis sold 1,406 shares of the stock in a transaction on Friday, October 31st. The shares were sold at an average price of $26.91, for a total value of $37,835.46. Following the completion of the sale, the director owned 9,841 shares of the company’s stock, valued at $264,821.31. The trade was a 12.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 35,302 shares of company stock valued at $1,036,449.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Stifel Nicolaus reaffirmed its Buy rating on Beta Bionics, supporting the view that some sell‑side analysts still see upside. Stifel Nicolaus Reaffirms Their Buy Rating on Beta Bionics, Inc. (BBNX)
• Positive Sentiment: Lake Street also maintained its Buy rating, another signal that some analysts continue to back the company’s longer‑term prospects. Lake Street Keeps Their Buy Rating on Beta Bionics, Inc. (BBNX)
• Neutral Sentiment: Comparative coverage: a head‑to‑head survey article compares Beta Bionics to Tenon Medical — useful for competitive context but not an immediate catalyst. Head-To-Head Survey: Beta Bionics (NASDAQ:BBNX) vs. Tenon Medical (NASDAQ:TNON)
• Negative Sentiment: Multiple law firms announced securities‑fraud investigations into Beta Bionics (DJS Law Group, Frank R. Cruz, Faruqi & Faruqi). These notices typically follow an adverse disclosure or results that could prompt litigation risk and increased investor caution. Beta Bionics, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights – BBNX
• Negative Sentiment: Additional firm-led probes were announced (Frank R. Cruz and Faruqi & Faruqi), each urging investors who lost money to inquire about claims — these amplify legal and reputational risk and often lead to selling pressure. INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
• Negative Sentiment: The Law Offices of Frank R. Cruz separately announced an investigation tied to Beta Bionics’ January disclosures, reinforcing legal risk headlines. Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
• Negative Sentiment: Short interest jumped materially in December to about 7.30M shares (≈16.6% of shares short), a large rise that can amplify downside pressure and increase volatility if holders cover. This higher short interest is a direct bearish signal. (Data entry)
• Neutral Sentiment: There is a reporting anomaly on short interest as of Jan. 12 showing zero shares — treat that as likely erroneous and rely on the Dec. 31 figure until corrected. (Data entry)
• Negative Sentiment: Bank of America cut Beta Bionics to Neutral, removing a prior bullish stance and reducing buy‑side support from a major institutional analyst. Beta Bionics (NASDAQ:BBNX) Cut to Neutral at Bank of America

Hedge Funds Weigh In On Beta Bionics

Large investors have recently made changes to their positions in the business. GPS Wealth Strategies Group LLC boosted its holdings in shares of Beta Bionics by 45.0% during the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the period. Strs Ohio acquired a new position in Beta Bionics in the 1st quarter valued at approximately $29,000. EverSource Wealth Advisors LLC lifted its position in Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after buying an additional 1,594 shares in the last quarter. CWM LLC acquired a new stake in shares of Beta Bionics during the 2nd quarter valued at $58,000. Finally, Legal & General Group Plc grew its holdings in shares of Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after acquiring an additional 2,639 shares in the last quarter.

Beta Bionics Trading Down 12.4%

The firm has a market capitalization of $777.13 million and a PE ratio of -4.04. The firm’s fifty day moving average price is $29.08 and its 200 day moving average price is $22.39.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.The firm had revenue of $27.25 million during the quarter, compared to analysts’ expectations of $23.92 million.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.